Mayflower Financial Advisors LLC Grows Position in Johnson & Johnson (NYSE:JNJ)

Mayflower Financial Advisors LLC raised its holdings in Johnson & Johnson (NYSE:JNJ) by 1.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,277 shares of the company’s stock after acquiring an additional 165 shares during the period. Mayflower Financial Advisors LLC’s holdings in Johnson & Johnson were worth $2,533,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Brighton Jones LLC raised its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Hudson Value Partners LLC raised its holdings in shares of Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock valued at $5,648,000 after buying an additional 1,022 shares in the last quarter. Proficio Capital Partners LLC raised its holdings in shares of Johnson & Johnson by 22.0% during the 4th quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company’s stock valued at $2,885,000 after buying an additional 3,594 shares in the last quarter. Horizon Investments LLC raised its holdings in shares of Johnson & Johnson by 10.1% during the 4th quarter. Horizon Investments LLC now owns 25,627 shares of the company’s stock valued at $3,706,000 after buying an additional 2,361 shares in the last quarter. Finally, Brooklyn FI LLC raised its holdings in shares of Johnson & Johnson by 6,239.7% during the 4th quarter. Brooklyn FI LLC now owns 127,682 shares of the company’s stock valued at $19,795,000 after buying an additional 125,668 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $164.78 on Thursday. The firm has a market cap of $396.47 billion, a P/E ratio of 18.33, a P/E/G ratio of 2.12 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The business’s 50 day moving average price is $153.95 and its 200-day moving average price is $154.71. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $2.82 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.16%. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

Analysts Set New Price Targets

A number of brokerages recently weighed in on JNJ. Bank of America decreased their price objective on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Leerink Partnrs cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Morgan Stanley reissued an “underperform” rating on shares of Johnson & Johnson in a report on Thursday, July 10th. Royal Bank Of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Finally, The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.